80 related articles for article (PubMed ID: 32945859)
1. Targeting DNA methylation.
Issa JP; Kantarjian HM
Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA methylation for epigenetic therapy.
Yang X; Lay F; Han H; Jones PA
Trends Pharmacol Sci; 2010 Nov; 31(11):536-46. PubMed ID: 20846732
[TBL] [Abstract][Full Text] [Related]
3. [Decitabine-cedazuridine as first line in acute myeloid leukaemia ineligible for conventional induction chemotherapy].
Tauveron-Jalenques U; Lambert J
Bull Cancer; 2024 May; 111(5):435-436. PubMed ID: 38582741
[No Abstract] [Full Text] [Related]
4. Correction to: Decitabine/Cedazuridine: First Approval.
Dhillon S
Drugs; 2021 Jan; 81(1):179. PubMed ID: 33369722
[No Abstract] [Full Text] [Related]
5. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
[TBL] [Abstract][Full Text] [Related]
6. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
7. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Garcia-Manero G; Griffiths EA; Steensma DP; Roboz GJ; Wells R; McCloskey J; Odenike O; DeZern AE; Yee K; Busque L; O'Connell C; Michaelis LC; Brandwein J; Kantarjian H; Oganesian A; Azab M; Savona MR
Blood; 2020 Aug; 136(6):674-683. PubMed ID: 32285126
[TBL] [Abstract][Full Text] [Related]
8. Decitabine and Cedazuridine.
Am J Health Syst Pharm; 2020 Oct; 77(22):1809-1811. PubMed ID: 32945859
[No Abstract] [Full Text] [Related]
9. Decitabine/Cedazuridine: First Approval.
Dhillon S
Drugs; 2020 Sep; 80(13):1373-1378. PubMed ID: 32860582
[TBL] [Abstract][Full Text] [Related]
10. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]